Press Release: Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference

Press Release: Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference


 
   UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. 
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing 
innovative bispecific antibody therapeutics, today announced that the 
Company will present at the 2016 Wedbush PacGrow Healthcare Conference 
on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New 
York City. 
 
   A live webcast of the presentation will be available on the Investor 
page of the Company's website. An archived presentation will be 
available for 90 days. 
 
   About Merus N.V. 
 
   Merus is a clinical-stage immuno-oncology company developing innovative 
full length human bispecific antibody therapeutics, referred to as 
Biclonics(R). Biclonics(R) are based on the full-length IgG format, are 
manufactured using industry standard processes and have been observed in 
preclinical studies to have several of the same features of conventional 
monoclonal antibodies, such as long half-life and low immunogenicity. 
Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated 
in a Phase 1/2 clinical trial in Europe as a potential treatment for 
HER2-expressing solid tumors. Merus' second bispecific antibody 
candidate, MCLA-117, is being developed as a potential treatment for 
acute myeloid leukemia. The Company also has a pipeline of proprietary 
bispecific antibody candidates in preclinical development, including 
MCLA-158, which is designed to bind to cancer stem cells and is being 
developed as a potential treatment for colorectal cancer and other solid 
tumors, and Biclonics(R) designed to bind to various combinations of 
immunomodulatory molecules, including PD-1 and PD-L1. 
 
Merus N.V. 
Shelley Margetson - s.margetson[a]merus.nl 
+31 (0)30 253 8800 
 
Argot Partners 
Kimberly Minarovich - kimberly[a]argotpartners.com 
1-212-600-1902 
   This announcement is distributed by NASDAQ OMX Corporate Solutions on 
behalf of NASDAQ OMX Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Merus N.V. via Globenewswire 
 
   HUG#2033933 
 
 
  http://www.merus.nl/ 
 
 Stock Market Quotes, Business News, Financial News from http://commodity-market-news.com